Compare Stocks → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:FIECVE:FRENASDAQ:GNFT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFIEiShares Canadian Financial Monthly Income ETF Common Class7.23+0.3%7.115.93▼7.24$968.82MN/A143,034 shs110,850 shsFREFremont GoldC$0.10+11.1%C$0.09C$0.05▼C$0.14C$3.79M0.0923,580 shs2,000 shsGNFTGenfit$3.76-1.1%$3.57$2.89▼$4.75$187.32M1.064,190 shs6,449 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFIEiShares Canadian Financial Monthly Income ETF Common Class+0.28%+0.42%+3.88%+3.14%+8.56%FREFremont Gold0.00%+11.11%+17.65%+53.85%-20.00%GNFTGenfit-4.21%-4.21%+5.20%-4.96%-14.39%4 Cryptos BETTER than Bitcoin (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFIEiShares Canadian Financial Monthly Income ETF Common ClassN/AN/AN/AN/AN/AN/AN/AN/AFREFremont GoldN/AN/AN/AN/AN/AN/AN/AN/AGNFTGenfit1.2115 of 5 stars3.53.00.00.02.00.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFIEiShares Canadian Financial Monthly Income ETF Common ClassN/AN/AN/AN/AFREFremont GoldN/AN/AN/AN/AGNFTGenfit3.00Buy$11.00192.62% UpsideCurrent Analyst RatingsLatest FRE, EI, FIE, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.004/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00(Data available from 5/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFIEiShares Canadian Financial Monthly Income ETF Common ClassN/AN/AN/AN/AN/AN/AFREFremont GoldN/AN/AC$0.05 per share1.84C$0.05 per shareN/AGNFTGenfit$41.31M4.53N/AN/A$1.48 per share2.54Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFIEiShares Canadian Financial Monthly Income ETF Common ClassN/AN/A0.00∞N/AN/AN/AN/AN/AFREFremont Gold-C$2.18M-C$0.07N/A∞N/AN/A-88.32%-39.85%N/AGNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFIEiShares Canadian Financial Monthly Income ETF Common Class0.486.64%N/AN/AN/AFREFremont GoldN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFIEiShares Canadian Financial Monthly Income ETF Common ClassN/AN/AN/AFREFremont GoldN/A0.921.79GNFTGenfit0.922.942.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFIEiShares Canadian Financial Monthly Income ETF Common ClassN/AFREFremont Gold1.05%GNFTGenfit2.24%Insider OwnershipCompanyInsider OwnershipFIEiShares Canadian Financial Monthly Income ETF Common ClassN/AFREFremont Gold25.48%GNFTGenfit4.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableFIEiShares Canadian Financial Monthly Income ETF Common ClassN/A134.00 millionN/ANot OptionableFREFremont GoldN/A37.92 millionN/ANot OptionableGNFTGenfit15949.83 million47.74 millionNot OptionableFRE, EI, FIE, and GNFT HeadlinesRecent News About These CompaniesMay 17 at 6:34 PM | marketbeat.comShort Interest in Genfit S.A. (NASDAQ:GNFT) Decreases By 5.8%May 15 at 11:09 AM | marketbeat.comHC Wainwright Reaffirms Buy Rating for Genfit (NASDAQ:GNFT)May 15 at 5:48 AM | finanznachrichten.deGENFIT S.A.: GENFIT Reports First Quarter 2024 Financial InformationMay 14, 2024 | globenewswire.comGENFIT Reports First Quarter 2024 Financial InformationApril 27, 2024 | marketbeat.comGenfit (NASDAQ:GNFT) Stock Price Up 1.2%April 25, 2024 | globenewswire.comGENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)April 15, 2024 | globenewswire.comGENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory DocumentsApril 5, 2024 | globenewswire.comGENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-FApril 5, 2024 | finanznachrichten.deGENFIT S.A.: GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate UpdateApril 4, 2024 | globenewswire.comGENFIT Reports Full-Year 2023 Financial Results and Provides Corporate UpdateApril 3, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday TradingMarch 27, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday TradingFebruary 29, 2024 | globenewswire.comGENFIT Announces Revenues and Cash Position as of December 31, 2023February 25, 2024 | thestreet.comGENFIT S.A.February 16, 2024 | msn.comInventiva drops after adverse event in Phase 3 trial for NASH drugFebruary 5, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday TradingJanuary 29, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Monday TradingDecember 21, 2023 | benzinga.comGenfit Stock (NASDAQ:GNFT) Dividends: History, Yield and DatesDecember 20, 2023 | morningstar.comGenfit SA ADR GNFTDecember 7, 2023 | msn.comFDA grants priority review of Genfit-Ipsen liver disease drugDecember 7, 2023 | markets.businessinsider.comIpsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesBoston Scientific Bucks the Medtech Slow Down and Raises OutlookApril 30, 2024 10:34 AMView Boston Scientific Bucks the Medtech Slow Down and Raises Outlook3 Value Stocks You Can Buy Before They Become BigMay 6, 2024 8:00 AMView 3 Value Stocks You Can Buy Before They Become BigCharles Schwab Fortifies its Uptrend on EPS Beat April 23, 2024 10:15 AMView Charles Schwab Fortifies its Uptrend on EPS Beat Lockheed Martin Stock Aims for a Fresh All-Time HighApril 23, 2024 9:59 AMView Lockheed Martin Stock Aims for a Fresh All-Time HighHigh-Yield Texas Instruments Could Hit New Highs SoonApril 24, 2024 11:27 AMView High-Yield Texas Instruments Could Hit New Highs SoonAll HeadlinesCompany DescriptionsiShares Canadian Financial Monthly Income ETF Common ClassTSE:FIEFremont GoldCVE:FREFremont Gold Ltd., an exploration stage company, engages in the acquisition, exploration, and evaluation of mineral properties in the United States and Canada. The company explores for gold and copper deposit. The company was formerly known as Palisades Ventures Inc. and changed its name to Fremont Gold Ltd. in June 2017. Fremont Gold Ltd. was incorporated in 2007 and is headquartered in Vancouver, Canada.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
